VANCOUVER, WA -- (MARKET WIRE) -- January 09, 2007 -- RS Medical announced today that it has acquired the assets of CFS Medical AB, a medical technology company based in Sweden. The agreement gives RS Medical access to a unique, patented technology called Cutaneous Field Stimulation (CFS), which has been shown to reduce pain and improve function when traditional electrotherapy is ineffective. CFS has also been clinically proven to be an effective, drug-free treatment for chronic itch, a pain syndrome affecting 24 million people in the US.
"Cutaneous Field Stimulation was developed by leading researchers in neurophysiology and we are delighted to have the opportunity to incorporate this technology into our product line," said Rick Terrell, President of RS Medical. "CFS offers an effective new therapy option for patients and further enhances RS Medical's position as the leader in physician-prescribed electrotherapy devices."
RS Medical expects to launch its first device based on the CFS technology in 2008.
About RS Medical
With a sales force of approximately 360 serving physicians in more than 195 metropolitan markets, RS Medical is America's leading provider of physician-prescribed home electrotherapy devices. More than 750,000 patients have been treated with its stimulators since the company was founded in 1990. RS Medical products are supported by the most comprehensive physician and patient services in the industry. The company is constantly pursuing cutting edge technologies that can be integrated into its product line. For more information please visit www.rsmedical.com.
About CFS Medical AB
CFS Medical AB is a medical technology company that was founded in 1993 by scientists, neurosurgeons and engineers at the University of Lund, Sweden. The company focuses on developing therapeutic medical devices based on research findings in neurophysiology and consequent clinical research. For more information please visit http://www.cfs.se.
SOURCE: RS Medical
>>> Discuss This Story